A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH 1 Antagonist) in the Treatment of Major Depression
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The corticotropin-releasing hormone (CRH) system is implicated in the pathogenesis of several psychiatric disorders, including major depressive disorder. This study was designed to evaluate the safety and efficacy of CP-316,311, a selective nonpeptide antagonist of corticotropin-releasing hormone type 1 (CRH(1)) receptors, in the treatment of recurrent major depressive disorder. METHOD: Of a total of 167 patients with recurrent major depression who were screened, 123 were randomly assigned to receive 400 mg of CP-316,311 twice daily, or 100 mg of sertraline daily, or placebo in a 6-week fixed-dose, double-blind, double-dummy, parallel-group, placebo- and sertraline-controlled trial. The primary efficacy analysis compared the change in score from baseline to endpoint on the 17-item Hamilton Depression Rating Scale (HAM-D) between the CP-316,311 and placebo groups. A group sequential design was used to support early trial termination based on efficacy or futility at a planned interim analysis. RESULTS: The evaluable data set for the interim analysis included 28 patients in the CP-316,311 group, 31 patients in the placebo group, and 30 patients in the sertraline group. In the interim analysis, the change from baseline in the HAM-D score at the final visit was not significantly different between the CP-316,311 and placebo groups, while change from baseline between the sertraline and placebo groups was significantly different. Given these results, futility was declared for CP-316,311 and the trial was terminated. CONCLUSIONS: Although CP-316,311 was safe and well tolerated in this study population, it failed to demonstrate efficacy in the treatment of major depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another CRH1 receptor antagonist, CP-316,311, could not achieve a significant improvement of depressive symptoms compared to placebo [102].”
From The HPA Axis as Target for Depression (2024) · cites this paper as [102]
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
The role of corticotropin-releasing factor in depression and anxiety disorders
Arborelius, L., Owens, M., Plotsky, P., & Nemeroff, C. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1600001 · Cited by 1,378
Physiology and pharmacology of corticotropin-releasing factor.
Owens, M. J., & Nemeroff, C. B. (1991) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06673-6 · Cited by 1,142
Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705
Reduced Corticotropin Releasing Factor Binding Sites in the Frontal Cortex of Suicide Victims
Nemeroff, C. B. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800300075009 · Cited by 555
The Dexamethasone Suppression Test for Diagnosis and Prognosis in Psychiatry: Commentary and Review
Arana, G. W. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790350067012 · Cited by 526
Adrenal Gland Enlargement in Major Depression: A Computed Tomographic Study
Nemeroff, C. B. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820050048008 · Cited by 283
Nemeroff, C. B., Bissette, G., Akil, H., & Fink, M. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.158.1.59 · Cited by 254
Research works printed but not linked: 2
- Owens MJ, 1991, Pharmacol Rev, 43, 425
- Shelton RC, 1994, Clin Ther, 16, 768
Cited by
Stetler, C., & Miller, G. E. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31820ad12b · Cited by 1,123
“Although this result is based on a limited number of studies and should be interpreted with caution, it is markedly divergent from the widely accepted idea that depression is associated with CRH hypersecretion (12).”
ResultNeurobiological and psychiatric consequences of child abuse and neglect
Heim, C., Shugart, M., Craighead, W. E., & Nemeroff, C. B. (2010) · Developmental Psychobiology · doi:10.1002/dev.20494 · Cited by 613
“A second study of another CRH receptor antagonist showed no evidence of efficacy in major depression (Binneman et al., 2008).”
BackgroundAgomelatine, the first melatonergic antidepressant: discovery, characterization and development
de Bodinat, C., Guardiola-Lemaitre, B., Mocaër, E., Renard, P., Muñoz, C., & Millan, M. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3140 · Cited by 593
“Unfortunately, clinical trials have been disappointin”
Stress Hormone Regulation: Biological Role and Translation into Therapy
Holsboer, F., & Ising, M. (2010) · Annual Review of Psychology · doi:10.1146/annurev.psych.093008.100321 · Cited by 473
Neurobiological mechanisms in major depressive disorder
aan het Rot, M., Mathew, S. J., & Charney, D. S. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080697 · Cited by 470
“However, a recent study found no significant antidepressive effect of a drug with selective action on the corticotropin-releasing factor type 1 receptor.(71) In contrast, in a study that used the anesthetic ketamine, which has actions on both dopamine and glutamate, a single intravenous administration of a subanesthet…”
Result
Metadata
- Authors
- Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., & Stiger, T.
- Affiliations
- Pfizer (United States) (US)
- ORCID
- Qiu, Ruolun
- Venue
- American Journal of Psychiatry
- Published
- 2008-05
- Volume
- 165
- Issue
- 5
- Pages
- 617-620
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2129752568
- Cited by
- 254
- References
- 13
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 10 · 2023: 6 · 2022: 9 · 2021: 7 · 2020: 7 · 2019: 13 · 2018: 10 · 2017: 8 · 2016: 19 · 2015: 13 · 2014: 14 · 2013: 16 · 2012: 21
- FWCI
- 22.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- corticotropin-releasing factor, major depressive disorder, recurrent depression, sertraline, antidepressant efficacy, drug safety and tolerability, futility, interim analysis, group sequential designs
- MeSH terms
- CRF Receptor, Type 1, Adult, Aged, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Humans, Middle Aged, Surveys and Questionnaires, Treatment Outcome, Receptors, Corticotropin-Releasing Hormone, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH 1 Antagonist) in the Treatment of Major Depression. https://app.cochat.ai/papers/10.1176/appi.ajp.2008.07071199
- The paper
- Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., & Stiger, T. (2008). A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH 1 Antagonist) in the Treatment of Major Depression. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2008.07071199
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.